Long-term outcomes of patients receiving drug-eluting stents

CMAJ. Canadian Medical Association Journal

Volumn 180, Issue 2, 2009, Pages 167-174

  Philpott, Andrew C ^a   Southern, Danielle A ^a   Clement, Fiona M ^a   Galbraith, P Diane ^a   Traboulsi, Mouhieddin ^a   Knudtson, Merril L ^a   Ghali, William A ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; ANGIOPLASTY; ARTICLE; BARE METAL STENT; COMORBIDITY; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; REVASCULARIZATION; RISK FACTOR; SAFETY;

EID: 58849122835     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080050     Document Type: Article

References (39)

1. Feres F, Costa JR Jr, Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv 2006;68:83-8.
2. Ishikawa T, Mutoh M, Fuda Y, et al. Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. Circ J 2006;70:1091-2.
3. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
4. Manjappa N, Agarwal A, Cavusoglu E. Very late bare-metal stent thrombosis. A case report and review of the literature. J Invasive Cardiol 2006;18:E203-6.
5. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92.
6. Pasceri V, Pelliccia F, Cianfrocca C, et al. Very late thrombosis after sirolimus-eluting stent implantation. J Cardiovasc Med (Hagerstown) 2006;7:438-42.
7. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9.
8. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109:701-5.
9. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical Bayesian meta-analysis. Ann Intern Med 2003;138:777-86.
10. Serruys PW, Kutryk MJB, Ong ATL. Coronary artery stents. N Engl J Med 2006;354:483-95.
11. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
12. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
13. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
14. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
15. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
16. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
17. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004;109:487-93.
18. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34.
19. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
20. Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996;334:561-6.
21. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 2006;114:2154-62.
22. Jensen LO, Maeng M, Kaltoft A, et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007;50:463-70.
23. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19. Epub 2007 Feb 12.
24. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-402.
25. Ong AT, van Domburg RT, Aoki J, et al. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2006;47:1356-60.
26. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 2008;359:1330-42.
27. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
28. Ghali WA, Knudtson ML; APPROACH Investigators. Overview of "APPROACH": the Alberta provincial project for outcome assessment in coronary heart disease. Can J Cardiol 2000;16:1225-30.
29. Norris CM, Ghali WA, Knudtson ML, et al. Dealing with missing data in observational health care outcome analysis. J Clin Epidemiol 2000;53:377-83.
30. Southern DA, Norris CM, Quan H, et al. An administrative data merging solution for dealing with missing data in a clinical registry: adaptation from ICD-9 to ICD-10. BMC Med Res Methodol 2008;8:1.
31. Graham MM, Faris PD, Ghali WA, et al.; APPROACH Investigators (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease). Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort. Am Heart J 2001;142:254-61.
32. Fleming TR, Harrington DP. Counting processes and survival analysis. New York (NY): John Wiley & Sons; 1991.
33. Hastie TJ, Tibshirani RJ. Generalized additive models. New York (NY): Chapman & Hall; 1990.
34. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-40.
35. Marzocchi A, Saia F, Piovaccari G, et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 2007;115:3181-8.
36. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-104.
37. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-13.
38. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
39. Daemen J, Serruys PW. Drug-eluting stent update 2007: part II: unsettled issues. Circulation 2007;116:961-8.